Formosa Pharmaceuticals (台新藥) is a clinical stage biopharmaceutical company with primary focus in ophthalmology and oncology. Our flagship asset, APP13007 (Clobetasol Propionate ophthalmic suspension 0.05%) was recently approved by the US FDA (March, 2024) for the treatment of post-operative inflammation and pain following ocular surgery. In August, 2017, Formosa Pharmaceuticals completed the acquisition of Activus Pharma, based in Funabashi, Japan. With the acquisition of the Activus Pure Nanoparticle Technology (APNT) Platform, Formosa Pharmaceuticals enters the ophthalmology disease area with two late-preclinical assets and the goal of expanding the platform’s scope and application. APNT effectively reduces API particle size to improve dissolution and bioavailability without the drawbacks of heavy metal contamination other platforms often experience.
External link for Formosa Pharmaceuticals, Inc.
8F-6 No. 57 Fuxing North Road
Songshan District, Taipei City 105, TW
Formosa Pharmaceuticals, Inc. successfully participated in CPhI 2024 Milan! A heartfelt thanks to our partners and friends for connecting with us at CPhI! 🌈 🍕 🥂 🌟 Special thanks to the MSD team at Formosa Laboratories, Inc. for all the support they have provided us! #FormosaPharma #FormosaLab #CPhI2024Milan #APP13007 #ClobetasolBID #ADCBiosimilar
Exciting News: 🚀 The Next Generation Ophthalmic Steroid Is Now Available in the US! 🚀 Thrilled to announce the commercial U.S. launch of clobetasol propionate ophthalmic suspension 0.05% (APP13007) developed by Formosa Pharmaceuticals, Inc. This highly anticipated development brings a formidable therapy to ocular surgery patients in the U.S. in partnership with Eyenovia, Inc. #ClobetasolBID #APP13007 #USLaunch
✨ We are excited to share that Formosa Pharmaceuticals, Inc. has been honored with the esteemed Gold Medal 🏆 for the Go-Global Award 🌏 at the 2024 Taipei Biotech Awards! We express our sincere appreciation to our committed team members and the continuous support from our shareholders, suppliers, partners, and all stakeholders. ✨ Learn more: https://shorturl.at/sulJF
We are thrilled to share that Formosa Pharmaceuticals, Inc. will be participating in BIO-Europe 2024 digitally from Taiwan. The virtual meetings are scheduled for November 12–13, 2024. Mark your calendars as full partnering on partneringOne will commence on September 23. Stay tuned for meeting requests via partneringOne ▶ . #BIOEurope2024 #FormosaPharma #DigitalParticipation
Formosa Pharmaceuticals, Inc., wishes our partners, collaborators, colleagues, and friends, a happy Mid-Autumn Festival and prosperous year ahead.
Formosa Pharmaceuticals, Inc., is excited to announce the successful shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to Eyenovia, Inc. in the United States for Commercialization. This achievement signals a major advancement in delivering innovative ophthalmic therapies to the market for both Formosa Pharmaceuticals, Inc. and Bora Pharmaceuticals. https://shorturl.at/zxkLy 🚛 🛫 🚀 #ClobetasolPropionate #FirstShipment #Commercialization #ClobetasolBID
We are thrilled to share that Clobetasol Propionate Ophthalmic Suspension (APP13007) has achieved a significant milestone! It has successfully completed the review process with the Taiwan Food and Drug Administration (TFDA) and has been granted the Export License for Pharmaceuticals. 🛫 🎉 #TFDA #ExportLicense #APP13007 #Clobetasol
👨🔬 Dr. Erick Co, President & CEO at Formosa Pharmaceuticals, Inc., showcased our achievement in developing APP13007 using the APNT nanoparticle platform at the International Advanced Drug Delivery Symposium (IADDS) at National Tsing Hua University, Taiwan. 🏫 https://lnkd.in/g2uyYkRW #DrugDelivery #APNT #APP13007 #Nanotechnology
Thrilled to be visiting CPHI Milan this year! If you’re attending and would like to discuss potential collaborations, please don't hesitate to get in touch. Looking forward to connecting with partners, industry professionals, and exploring new opportunities. To Schedule a CPhI meeting with Formosa Pharmaceuticals, Inc.: https://shorturl.at/bvemV #APNT #ADCBiosimilar #APP13007 #OcularInflammation #CPhI
🎊 We are honored to share that Formosa Pharmaceuticals, Inc. (6838) has officially listed on the Taiwan Stock Exchange (TWSE) on August 13, 2024. ㊗ 我們非常榮幸地跟大家分享台新藥（6838）於2024年8月13日於臺灣證券交易所掛牌上市。 #APNT #APP13007 #6838 #TWSE